Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Medtronic PLC (MDT) vs T Rowe Price Group Inc (TROW) Price & Performance

Medtronic PLCTrade
T Rowe Price Group IncTrade

Price performance (Past 24H)

Key statistics

Medtronic PLC vs T Rowe Price Group Inc — how do they compare? Medtronic PLC trades at $82.57 (market cap $106.61B), while T Rowe Price Group Inc trades at $117.54 (market cap $25.14B). The key difference: Medtronic PLC is far larger — about 4.2× T Rowe Price Group Inc's market cap, and T Rowe Price Group Inc pays the higher dividend (4.43%). Which is the better fit depends on your goals.

MDTTROW
Market Cap
$106.61B$25.14B
Sector
HealthFinancials
52-Week High
$105.35$120.16
52-Week Low
$73.75$86.19
Enterprise Value
$125.36B$21.85B
Dividend Yield
3.46%4.43%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Medtronic PLC

Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.

The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.

T Rowe Price Group Inc

T. Rowe Price (TROW) trades at $116.345, down 0.86% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q1 2026 earnings that beat expectations, with revenue growth from $7.1B in 2024 to $7.3B in 2025 and a net income margin of 28.28%. Recent news highlights the launch of an active crypto ETF and AUM reaching $1.89 trillion in June 2026.

The outlook for TROW is mixed; valuation ratios like a P/E of 12.59 suggest potential undervaluation, but analyst consensus is cautious with a hold-heavy rating. Key risks include equity outflows and market volatility, while opportunities lie in diversified AUM growth and innovation. The stock's performance hinges on sustaining profitability amid competitive pressures.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Medtronic PLC

One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.

Read more on MDT

About T Rowe Price Group Inc

T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.

Read more on TROW